TITLE

Menthol cigarettes and health risks in Lung Health Study data

AUTHOR(S)
Murray, Robert P.; Connett, John E.; Skeans, Melissa A.; Tashkin, Donald P.
PUB. DATE
January 2007
SOURCE
Nicotine & Tobacco Research;Jan2007, Vol. 9 Issue 1, p101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Whether menthol cigarettes confer a higher risk of death than plain cigarettes is not known. The Lung Health Study (LHS) enrolled 5,887 adult smokers in a clinical trial of smoking cessation and ipratropium in the prevention of chronic obstructive pulmonary disease. LHS participants have been subjected to surveillance for mortality from all causes for 14 years. We examined these data for differences between self-reported smokers of menthol cigarettes versus plain cigarettes. Using proportional hazards regression methods, we found no differences in hazard ratios for coronary heart disease, cardiovascular disease, lung cancer, or death from any cause. Contrary to expectations about nicotine dependence, we found that users of menthol cigarettes had smoked fewer pack-years at baseline. We found no difference in success at smoking cessation with or without menthol. We conclude that our data contain no evidence that mentholation of cigarettes increases the hazards of smoking.
ACCESSION #
24078501

 

Related Articles

  • Cholecystokinin C-45T polymorphism and smoking cessation in women. Ton, Thanh G.; Rossing, Mary Anne; Bowen, Deborah J.; Wilkerson, Hui-Wen; Farin, Federico M. // Nicotine & Tobacco Research;Jan2007, Vol. 9 Issue 1, p147 

    In view of the effect of cholecystokinin (CCK) on dopaminergic neurons in the mesolimbic “reward” pathway of the brain, its gene has been a focus in studies of dopamine-related conditions and behaviors, including smoking. We assessed the association between the CCK C-45T polymorphism...

  • BUPROPION FOR SMOKING CESSATION. Jackson, Eric A. // Journal of Family Practice;Feb1998, Vol. 46 Issue 2, p111 

    The article discusses research being done on the use of bupropion and placebo for smoking cessation, with reference to a study by R. D. Hurt, D. P. L. Sachs, E. D. Glover et al, which appeared in the 1997 issue of the "New England Journal of Medicine." The randomized, double-blind study...

  • Achieving high rates of consent for genetic testing among African American smokers. Cox, Lisa Sanderson; Bronars, Carrie A.; Thomas, Janet L.; Okuyemi, Kolawole S.; King, Gary; Mayo, Matthew S.; Ahluwalia, Jasjit S. // Nicotine & Tobacco Research;Jun2007, Vol. 9 Issue 6, p711 

    Genetic factors play an important role in smoking behavior. Although African Americans are at disproportionately increased risk for tobacco-related morbidity and mortality, limited attention has been given to genetic investigation of tobacco use in this population. The present study examined...

  • Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. West, Robert; Xiaolei Zhou // Thorax;Nov2007, Vol. 62 Issue 11, p998 

    Background: Increasing smoking cessation rates is an important goal in preventing lung cancer and chronic obstructive pulmonary disease. Nicotine replacement therapy (NRT) has been found in clinical trials to improve the chances of success at stopping, but recent cross-sectional survey data have...

  • Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Kotz, Daniel // Journal of Medical Ethics;Sep2009, Vol. 35 Issue 9, p2 

    Background: Spirometry for early detection of chronic obstructive pulmonary disease (COPD) and smoking cessation is criticised because of the potential negative effects of labelling with disease. Aim: To assess the effects of opinions of smokers with mild to moderate COPD on the effectiveness of...

  • The efficacy of vigorous-intensity exercise as an aid to smoking cessation in adults with elevated anxiety sensitivity: study protocol for a randomized controlled trial. J. Smits, Jasper A.; Zvolensky, Michael J.; Rosenfield, David; Marcus, Bess H.; Church, Timothy S.; Frierson, Georita M.; Powers, Mark B.; Otto, Michael W.; Davis, Michelle L.; DeBoer, Lindsey B.; Briceno, Nicole F. // Trials;2012, Vol. 13 Issue 1, p207 

    Background: Although cigarette smoking is a leading cause of death and disability in the United States (US), over 40 million adults in the US currently smoke. Quitting smoking is particularly difficult for smokers with certain types of psychological vulnerability. Researchers have frequently...

  • Evotec's MAO-B Inhibitor Fails in Phase II Trial.  // Bioworld Week;4/20/2009, Vol. 17 Issue 16, p4 

    The article reports on the result of the Phase II clinical trial of smoking cessation drug called EVT 302 that failed to show improvement in the quit rate of smokers, and reassesses the manufacturer Evotec AG plans to reassess the drug following further analysis. EVT 302, a monoamine oxidase B...

  • First clinical trial involving only Maori. Kumar, Rajesh // New Zealand Doctor;2/9/2005, p6 

    Reveals that the drug bupropion is an effective smoking cessation treatment for Maori people in New Zealand based on a clinical trial report published in the "Thorax" periodical. Research who led the clinical trial.

  • Abciximab reduces adverse event risk in ACS patients pretreated with clopidogrel.  // Formulary;May2006, Vol. 41 Issue 5, p236 

    The article presents a summary of Intaracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial on abciximab's clinical benefits in patients with acute coronary syndromes (ACS) pretreated with clopidogrel. The study found out that the glycoprotein IIb/IIIa...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics